New research indicates that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle plans.
Findings released in a prominent medical journal points out that while obese people can lose a large proportion of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying these drugs need to be aware of the danger of rapid rebound weight gain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to original mass in about a year and a half.
Analyzing Approaches
The study, which reviewed 37 of trials involving over 9,000 of patients, contrasted the results of these new drugs with other pills.
The team emphasize that people who shed pounds through lifestyle changes alone usually see a slower creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Fast Rebound
Nutrition scientists propose the way of the jabs is key to understanding the heightened regain.
These medications copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating much more probable."
A Chronic Issue?
Health authorities suggest the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts argue that, due to the likelihood of weight regain, the treatment should be considered long-term.
This opinion is echoed by pharmaceutical companies, who say that the results "highlight the chronic character of excess weight," comparing it to managing conditions like hypertension.
User Testimonies
Users who have come off the medication explain a intense resurgence of hunger.
"It felt as if something flipping and I was suddenly extremely hungry," described one woman.
This difficulty is worsened if users have not adopted sustainable dietary or behavioural modifications during treatment.
Widespread Use
Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among women than males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, clinicians caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent cure and lasting health benefits relies on combined lifestyle management.
